EP4536226A1 — Process for preparation of selumetinib and salts thereof
Assigned to Alivus Life Sciences Ltd · Expires 2025-04-16 · 1y expired
What this patent protects
The present invention is related to a process of selumetinib, a compound of formula (II), or an acid addition salt thereof. The present invention is also related to an intermediate compound of formula (III) or a salt or a hydrate thereof, and its use thereof in the preparation of…
USPTO Abstract
The present invention is related to a process of selumetinib, a compound of formula (II), or an acid addition salt thereof. The present invention is also related to an intermediate compound of formula (III) or a salt or a hydrate thereof, and its use thereof in the preparation of selumetinib, or an acid addition salt thereof. The present invention is further related to a process for the preparation of an intermediate compound of formula (Va).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.